Skip to main content

MW 371.4 Da, Purity >98%. L-type Ca2+ channel blocker. Achieve your results faster with highly validated, pure and trusted compounds.

Be the first to review this product! Submit a review

Images

Chemical Structure - Isradipine, L-type Ca2+ channel blocker (AB120142), expandable thumbnail

Publications

Key facts

CAS number

75695-93-1

Purity

> 98%

Form

Solid

Molecular weight

371.4 Da

Molecular formula

C19H21N3O5

PubChem identifier

3784

Nature

Synthetic

Target data

Alternative names

(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,8-cineole 2-exo-monooxygenase, 2700049B16Rik, 3110031N04Rik, ABC member 16, MDR/TAP subfamily, ABC16, ABCB1, ABCBB_HUMAN, AIS, ANDR_HUMAN, AR, AR8, ASRT2, ATP binding cassette sub family B (MDR/TAP) member 11, ATP-binding cassette sub-family B member 11, Albendazole monooxygenase, Albendazole sulfoxidase, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Aryl hydrocarbon hydroxylase, BK channel, BK channel beta subunit, BK channel subunit beta-1, BK channel subunit beta-2, BK channel subunit beta-4, BKCA alpha, BKCA alpha subunit, BKTM, BKbeta, BKbeta1, BKbeta2, BKbeta4, BRIC2, BXR, Bile salt export pump, Bsep, CAC1C_HUMAN, CAC1D_HUMAN, CACH 2, CACH3, CACN 2, CACN4, CACNA 1D, CACNL1A1, CACNL1A2, CAPC, CCHL1A1, CCHL1A2, CP 12, CP1A2_HUMAN, CP2C9_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC12, CPC8, CPC9, CPCJ, CYP1A2, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIA2, CYPIIC9, CYPIIIA3, CYPIIIA4, CaV1.2, Calcium activated potassium channel beta 4 subunit, Calcium activated potassium channel subfamily M subunit beta 1, Calcium activated potassium channel subfamily M subunit beta 2, Calcium activated potassium channel subfamily M subunit beta 4, Calcium channel, Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle, Calcium channel L type alpha 1 polypeptide isoform 2, Calcium channel cardic dihydropyridine sensitive alpha 1 subunit, Calcium channel neuroendocrine/brain type alpha 1 subunit, Calcium channel voltage dependent L type alpha 1, Calcium channel voltage dependent L type alpha 1C subunit, Calcium channel voltage dependent L type alpha 1D subunit, Calcium-activated potassium channel, Calcium-activated potassium channel subunit alpha-1, Calcium-activated potassium channel subunit beta, Calcium-activated potassium channel subunit beta-1, Calcium-activated potassium channel subunit beta-2, Calcium-activated potassium channel subunit beta-4, Cav1.3, Charybdotoxin receptor subunit beta-1, Charybdotoxin receptor subunit beta-2, Charybdotoxin receptor subunit beta-4, Cytochrome P(3)450, Cytochrome P-450MP, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 4, Cytochrome P450 HLp, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 1 polypeptide 2, Cytochrome P450 family 1 subfamily A polypeptide 2, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily I aromatic compound inducible polypeptide 2, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-P3, Cytochrome P450-PCN1, Cytokeratin-associated protein in cancer, DHPR alpha 1, DHPR alpha 1 subunit, DHTR, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Dioxin inducable P3 450, Drosophila slowpoke like, G protein coupled receptor 154, G protein coupled receptor PGR14, G protein coupled receptor for asthma susceptibility, GPR 154, GPRA, Glucocorticoid inducible P450, HLP, HUMARA, HYSP1, Hbeta1, Hbeta2, Hbeta3, Hbeta4, K(VCA)alpha, K(VCA)beta, K(VCA)beta-1, K(VCA)beta-2, K(VCA)beta-4, KCMA1_HUMAN, KCMB1_HUMAN, KCMB2_HUMAN, KCMB4_HUMAN, KCNMA, KCNMA1, KCNMB 1, KCNMB 2, KCa1.1, KD, Kennedy disease (KD), L type, LQT8, LRC26_HUMAN, Large conductance Ca2+ activated K+ channel beta 1 subunit, Large conductance Ca2+ activated K+ channel beta2 subunit, Large conductance calcium activated potassium channel beta 2 subunit, Large conductance calcium dependent potassium ion channel beta 4 subunit, Leucine-rich repeat-containing protein 26, Lrrc26, MGC126680, MGC149605, MGC22431, MGC57945, MGC88320, MVTR, Maxi K channel, Maxi K channel beta subunit, Maxi K channel subunit beta-1, Maxi K channel subunit beta-2, Maxi K channel subunit beta-4, Maxi Potassium channel alpha, MaxiK, MaxiK channel beta 2 subunit, Microsomal monooxygenase, NF 25, NPSR, NR1B1, NR1I2_HUMAN, NR3C4, Neuropeptide S receptor, Neuropeptide S receptor 1, Nifedipine oxidase, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, ONR 1, OTTHUMP00000020135, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P(3)450, P3 450, P450 4, P450 III steroid inducible, P450 MP, P450 P3, P450 PB 1, P450 PCN1, P450 form 4, P450(PA), P450, family III, P450C2C, P450C3, P450IIC19, P450IIC9, PAR, PAR q, PASNA, PFIC 2, PGR 14, PGY4, PRR, Potassium large conductance calcium activated channel subfamily M beta member 1, Potassium large conductance calcium activated channel subfamily M beta member 2, Potassium large conductance calcium activated channel subfamily M beta member 4, Pregnane X receptor, Quinine 3-monooxygenase, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, S-mephenytoin 4-hydroxylase, SAKCA, SANDD, SBMA, SLO, SMAX1, SXR, Sister of P glycoprotein, Slo homolog, Slo-alpha, Slo-beta, Slo-beta-1, Slo-beta-2, Slo-beta-4, Slo1, Slowpoke homolog, Spgp, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, TFM, TS, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), VRR 1, Vasopressin receptor related receptor 1, Voltage dependent L type calcium channel alpha 1C subunit, Voltage gated L type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*, Voltage gated calcium channel alpha 1 subunit, Voltage gated calcium channel alpha subunit Cav1.2, Voltage gated calcium channel alpha subunit Cav1.3, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-dependent L-type calcium channel subunit alpha-1D, Voltage-gated calcium channel subunit alpha Cav1.2, Voltage-gated calcium channel subunit alpha Cav1.3, Xenobiotic monooxygenase, alpha-1 polypeptide, androgen receptor splice variant 4b, bA350O14.10, cardiac muscle, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, cytokeratin-associated protein, flavoprotein-linked monooxygenase, hSlo, hslo beta, isoform 1, isoform 2, nps receptor, pregnane X nuclear receptor variant 2, progressive familial intrahepatic cholestasis 2, subfamily M subunit alpha-1, subfamily M subunit beta-1, subfamily M subunit beta-2, subfamily M subunit beta-4

Recommended products

MW 371.4 Da, Purity >98%. L-type Ca2+ channel blocker. Achieve your results faster with highly validated, pure and trusted compounds.

Key facts

Purity

> 98%

PubChem identifier

3784

Solubility

Soluble in DMSO to 100 mM. Soluble in ethanol to 50 mM.

Biochemical name

Isradipine

Biological description

L-type Ca2+ channel blocker.

Canonical SMILES

CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC

InChI

InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3

InChIKey

HMJIYCCIJYRONP-UHFFFAOYSA-N

IUPAC name

3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

Storage

Shipped at conditions

Ambient - Can Ship with Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

+4°C

Storage information

Store under desiccating conditions, The product can be stored for up to 12 months

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The biological targets CACNA1C Cytochrome P450 enzymes (including 1A2 3A4 2C9 2C8 2C19 2C12) Androgen Receptor Retinoic Acid Receptor alpha PXR Maxi Potassium channels (alpha SLO and beta subunits KCNMB1 KCNMB2 KCNMB4 and LRRC26) and ABCB11/BSEP play diverse mechanical roles in cellular physiology. For example CACNA1C also known as Cav1.2 is a voltage-dependent calcium channel with a mass of about 240 kDa. It is expressed in the heart brain and skeletal muscles where it facilitates the influx of calcium ions. The Maxi Potassium channels contribute to cell membrane potential regulation through their high conductance. Cytochrome P450 enzymes such as CYP3A4 are involved in the metabolism of drugs and xenobiotics expressed mainly in the liver. The Androgen Receptor is important in mediating the effects of androgens and is widely present in the prostate and other tissues.

Biological function summary

These targets perform roles critical to physiological processes. CACNA1C regulates cardiac action potential and muscle contraction acting in concert with other subunits to form a functional complex. Cytochrome P450 enzymes metabolize endogenous and exogenous compounds maintaining chemical homeostasis. The Androgen Receptor modulates gene expression upon binding testosterone or dihydrotestosterone. Retinoic Acid Receptor alpha influences gene transcription affecting cell differentiation and growth. The Retinoic Acid Receptor and PXR often function within complexes to control gene expression affecting xenobiotic metabolism.

Pathways

The functions of these proteins integrate into central biological networks. CACNA1C participates in the cardiac contraction pathway influencing heart muscle function. Cytochrome P450 enzymes like CYP3A4 and CYP2C9 are integral to drug metabolism and xenobiotic pathways interacting with multiple proteins for efficient biotransformation. The Androgen Receptor plays a role in the androgen signaling pathway impacting proteins such as cortisol convertases. Maxi Potassium channels including KCNMB1 and KCNMB4 are involved in pathways regulating cellular excitability and neurotransmitter release.

Associated diseases and disorders

These targets have associations with significant clinical implications. Mutations or dysregulation of CACNA1C can lead to cardiac disorders like Timothy syndrome. Cytochrome P450 enzymes particularly CYP3A4 and CYP2C9 are linked to altered pharmacokinetics in liver diseases impacting drug efficacy and safety. The Androgen Receptor's involvement in prostate cancer highlights its role in regulating cell growth with therapeutic strategies targeting its activity. Additionally ABCB11/BSEP mutations relate to liver diseases such as progressive familial intrahepatic cholestasis linked with bile acid transport dysfunction.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Chemical Structure - Isradipine, L-type Ca2+ channel blocker (ab120142), expandable thumbnail

    Chemical Structure - Isradipine, L-type Ca2+ channel blocker (ab120142)

    2D chemical structure image of ab120142, Isradipine, L-type Ca2+ channel blocker

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com